Eric K. Singhi: Is it time to universally prescribe 1L lorlatinib for all?
Eric K. Singhi, Assistant Professor in the Department of General Oncology within the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, shared a post on X:
“While small numbers from this phase 2 JTO and JTO CRR study, 5-year OS data seems to support 1L lorlatinib (76%!)
With this and updated CROWN data, is it time to universally prescribe 1L lorlatinib for all?”
Authors: Sai-Hong Ignatius Ou, Benjamin J. Solomon, Benjamin Besse, Alessandra Bearz, Chia-Chi Lin, Rita Chiari, D. Ross Camidge, Jessica J. Lin, Antonello Abbattista, Francesca Toffalorio, Ross A. Soo
Eric K. Singhi is a thoracic and head and neck medical oncologist, currently serving as an Assistant Professor in the Department of General Oncology within the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, TX.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023